Advertisement

 

 

Anakinra Ineffective for Reducing Symptoms of Chronic Fatigue

Anakinra Ineffective for Reducing Symptoms of Chronic Fatigue
Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

TUESDAY, March 7, 2017 (HealthDay News) — The anti-inflammatory biologic drug anakinra (Kineret) does not reduce fatigue severity in women with chronic fatigue syndrome, according to a study published online March 7 in the Annals of Internal Medicine.

To test anakinra’s potential as a treatment, Megan E. Roerink, M.D., of the Radboud University Medical Centre in Nijmegen, Netherlands, and colleagues randomly assigned 25 women with chronic fatigue syndrome to receive daily 100-mg injections of the drug. Another 25 women received a placebo.

After one month, the researchers saw no meaningful difference between the two groups in fatigue severity. Other symptoms — including pain, distress, and physical and social functioning — were not appreciably different, either.

“Peripheral interleukin-1 inhibition using anakinra for four weeks does not result in a clinically significant reduction in fatigue severity in women with chronic fatigue syndrome and severe fatigue,” the authors write.

Abstract/Full Text (subscription or payment may be required)

Copyright © 2017 HealthDay. All rights reserved.
healthday

Submit a Comment

Your email address will not be published. Required fields are marked *

16 + 17 =

[ HIDE/SHOW ]